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A B S T R A C T   
Type-1 diabetes mellitus (T1DM) is associated with metabolic changes leading to alterations in glucose and lipid 
handling. While T1DM-associated effects on many major plasma lipids have been characterised, such effects on 
plasma free fatty acids (FFA) have not been fully examined. Using gas chromatography–mass spectrometry, we 
measured the plasma concentrations of FFA species in individuals with T1DM (n = 44) and age/sex-matched 
healthy controls (n = 44). Relationships between FFA species and various parameters were evaluated. Plasma 
concentrations of myristate (14:0), palmitoleate (16:1), palmitate (16:0), linoleate (18:2), oleate (18:1c9), cis- 
vaccenate (18:1c11), eicosapentaenoate (20:5), arachidonate (20:4) and docosahexanoate (22:6) were reduced 
in the T1DM group (p  <  0.0001 for all, except p = 0.0020 for eicosapentaenoate and p = 0.0068 for ara-
chidonate); α-linolenate (18:3) and dihomo-γ-linolenate (20:3) concentrations were unchanged. The saturated/ 
unsaturated FFA ratio, n-3/n-6 ratio, de novo lipogenesis index (palmitate (main lipogenesis product)/linoleate 
(only found in diet)) and elongase index (oleate/palmitoleate) were increased in the T1DM group (p = 0.0166, 
p = 0.0089, p  <  0.0001 and p = 0.0008 respectively). The stearoyl-CoA desaturase 1 (SCD1) index 1 (pal-
mitoleate/palmitate) and index 2 (oleate/stearate) were reduced in T1DM (p  <  0.0001 for both). The delta-(5)- 
desaturase (D5D) index (arachidonate/dihomo-γ-linolenate) was unchanged. Age and sex had no effect on 
plasma FFA concentrations in T1DM, while SCD1 index 1 was positively correlated (p = 0.098) and elongase 
index negatively correlated with age (p = 0.0363). HbA1c was negatively correlated with all plasma FFA 
concentrations measured except α-linolenate and dihomo-γ-linolenate. Correlations were observed between 
plasma FFA concentrations and cholesterol and HDL concentrations, but not LDL concentration or diabetes 
duration. Collectively, these results aid our understanding of T1DM and its effects on lipid metabolism.   
1. Introduction 
Type-1 diabetes mellitus (T1DM) is an immune disease in which the 
β-cells in the islets of the pancreas are destroyed, resulting in impaired 
insulin secretion and control of blood glucose [1]. Worldwide incidence 
varies, with age-adjusted incidences ranging from 0.1/100,000 new 
occurrences per year in China and Venezuela to 36.5 and 36.8/100,000 
new occurrences per year in Finland and Sardinia, respectively [2]. 
Dysregulation of plasma insulin and glucose concentrations in T1DM 
can lead to a range of metabolic changes [3,4]. In particular, plasma 
lipid composition is known to be altered in individuals with T1DM, as 
shown by several lipidomic studies [5–8]. However, many of those 
studies focus on infants and young children, to investigate the devel-
opment of T1DM, rather than the characteristics of the established 
disease in adults [3,9–15]. Moreover, the previous work has primarily 
focussed on lipoproteins, cholesterol and esterified fatty acids, while 
non-esterified or “free” fatty acids (FFAs) have had much less attention. 
This is because they are more sensitive to daily metabolic variations 
than other lipids. 
FFAs are important signalling molecules and as well as being an 
important source of energy, impact on numerous physiological pro-
cesses, including the regulation of inflammation, the management of 
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oxidative stress, the composition of cellular membranes and signal 
transduction, as recently reviewed by us [16]. Thus, changes in the 
composition of plasma FFAs can potentially cause further complications 
in individuals with T1DM and, while they reflect a wider dysregulation 
of lipid metabolism, they can also be altered in different ways to other 
lipids and thus are worthy of further study in their own right [16]. 
Important aspects of the plasma FFA profile are the saturated/un-
saturated FFA ratio and the n-3/n-6 ratio as those directly impact the 
physiological processes mentioned above. In addition, the concentra-
tions of specific FFAs species can be used to calculate indices reflecting 
desaturation, elongation and de novo lipogenesis activity. Thus, to gain 
insight into how T1DM influences the plasma FFA profile, we measured 
and compared plasma concentrations of major FFA species in in-
dividuals with T1DM and an age/sex-matched control group without 
diabetes. In addition, we explored how plasma FFA concentrations and 
lipid indices compare with sex, age and the concentrations of glycated 
haemoglobin A1c (HbA1c) and diverse lipids. 
2. Materials and methods 
2.1. Clinical sample collection 
A total of 44 individuals with T1DM and 44 controls were recruited 
from Leeds Teaching Hospital Trust following approval by the Leeds 
West Research Ethics Committee (REC: 09/H1307/12). We excluded 
individuals with a history of acute coronary syndrome or those that had 
experienced a stroke within 3 months of enrolment, individuals who 
had received prior treatment with aspirin, clopidogrel, warfarin or non- 
steroidal anti-inflammatory drugs or who had a current treatment with 
any drug other than insulin, individuals with a history of deep venous 
thrombosis or pulmonary embolism, previous or current history of 
upper gastrointestinal pathology, malignancy or coagulation disorders, 
individuals with abnormal liver function tests (alanine transami-
nase > 3 fold upper limit of normal) or abnormal thyroid function tests 
and individuals with proteinuria, advanced nephropathy or clinical 
signs of neuropathy or retinopathy (except for those with background 
changes). Written informed consent was obtained. All blood samples 
were collected after a light breakfast (to avoid hypoglycaemia in T1DM 
individuals) and within 2 h the blood was centrifuged at 2400 ×g for 
20 min at 4 °C. The plasma was snap frozen in liquid nitrogen and 
stored at −40 °C until analysis. Plasma concentration of human serum 
albumin (HSA), HbA1c, fasting glucose, triglycerides, cholesterol, high- 
density lipoprotein (HDL) and low-density lipoprotein (LDL) were 
measured with routine methods. 
2.2. Measurement of plasma FAMEs 
In order to characterise the FFAs present in each sample, they were 
converted to fatty acid methyl esters (FAMEs) and analysed by gas 
chromatography–mass spectrometry (GC–MS) analysis. This was per-
formed by thawing the citrated plasma samples and spiking them with 
an internal standard (heptadecanoate; 17:0, 100 pmoles) to allow for 
normalisation. Dole's protocol was used to extract the FFAs [17], and 
the FFAs were converted to FAMEs by incubating them for 5 h at 45 °C 
with 1500 μl of methanol, 200 μl of toluene and 300 μl of 8% HCl. 
Nitrogen was used to evaporate the samples to dryness. The FAMEs 
were dissolved in 500 μl of water and 500 μl of hexane and the hexane 
phase was collected. The samples were left to evaporate to dryness in a 
fume hood. The FAMEs were then dissolved in 30 μl dichloromethane 
and analysed by GC–MS using 1–2 μl of the resultant samples. The in-
strument used was a GC-6890 N, MS detector-5973 (Agilent Technol-
ogies, Santa Clara, CA, USA) with a ZB-5 column 
(30 m × 25 mm × 25 mm; Phenomenex, Torrance, CA, USA). The 
temperature program was: at 70 °C for 10 min, followed by a gradient 
to 220 °C at 5 °C /min, and held at 220 °C for a further 15 min. The mass 
spectra were acquired from 50 to 500 amu. The FAMEs were identified 
by comparison of the retention time and fragmentation pattern of the 
samples with that of various FAME standard mixtures (Supelco, Belle-
fonte, PA, USA) as previously described [18]. 
2.3. Data analysis and representation 
Differences between groups were analysed using multiple Student's 
t-tests or, for continuous parameters, using Pearson's correlation test. 
The significance threshold was set at p ≤ 0.05. Statistical analyses were 
performed and graphs were generated with Prism 8.2.1 (GraphPad 
Software, La Jolla, CA, USA). Data are represented as mean  ±  
standard deviation (SD). 
3. Results 
3.1. Demographic information and measure of plasma concentrations of 
different molecules 
In addition to collected demographic information, plasma con-
centration of triglycerides, cholesterol, LDL, HDL, HbA1c and HSA were 
measured and the cholesterol ratio was calculated subjects with T1DM 
and the controls. Summaries of this data are presented in Table 1, Fig. 1 
and Table S1. The T1DM and control groups were matched for age and 
sex, but the T1DM group had a higher BMI (p = 0.0359). There was no 
difference in the concentrations of triglycerides, cholesterol, LDL, HDL 
and cholesterol ratio between the groups. In the T1DM group, HbA1c 
was higher (p  <  0.0001) and HSA was lower (p = 0.0413) compared 
to controls. 
3.2. T1DM-associated changes in FFA concentrations and plasma indices 
A FAME analysis was carried out on plasma samples from both 
Table 1 
Demographic information on the T1DM and control groups. Where differences are significant, the p-value is provided. Where no significant difference was observed 
(p  >  0.05), it is denoted by ns.         
Controls (n = 44) T1DM subjects (n = 44) Statistical significance 
Mean SD Mean SD P values  
Age (years) 24.1 6.2  26.4 6.8 ns 
Sex (% of male) 55 –  59 – ns 
Height (m) 1.73 0.10  1.73 0.10 ns 
BMI (kg/m2) 23.1 3.0  24.6 3.5 0.0359 
Numbers of smoking individuals 2 –  13 – – 
Numbers of macrovascular events 0 –  0 – – 
Numbers of microvascular events 0 –  1 – – 
Numbers of individuals with familial history of autoimmunity 11 –  16 – – 
Numbers of individuals with familial history of Huntington's disease 15 –  9 – – 
Diabetes duration (months) – –  125 103 – 
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T1DM and control groups to identify and quantify the major FFA spe-
cies (Fig. 2 and Table S2). With the exception of α-linolenate (18:3) and 
dihomo-γ-linolenate (20:3), the concentrations of all major FFA species 
are lower in plasma taken from the T1DM group compared to controls: 
myristate (14:0; p  <  0.0001), palmitoleate (16:1; p  <  0.0001), pal-
mitate (16:0; p  <  0.0001), linoleate (18:2; p  <  0.0001), oleate 
(18:1c9; p  <  0.0001), cis-vaccenate (18:1c11; p  <  0.0001), stearate 
(18:0; p  <  0.0001), eicosapentaenoate (20:5; p = 0.0020), arachido-
nate (20:4; p = 0.0068) and docosahexaenoate (22:6, p  <  0.0001). 
Different plasma FFA indices were then calculated and compared 
between the T1DM and control groups (Fig. 3 and Table S3). Plasma 
concentration of total FFAs, total saturated FFAs, total unsaturated 
FFAs, total n-6 FFAs and total n-3 FFAs were lower in the T1DM group 
than in the controls (p  <  0.0001 for all). The saturated/unsaturated 
FFA ratio and n-3/n-6 ratio were higher in the T1DM group 
(p = 0.0166 and p = 0.0089 respectively). The de novo lipogenesis 
index was calculated as the ratio of palmitate (16:0, the main product of 
lipogenesis) with linoleate (18:2, an essential FFA only found in the 
diet). The elongase index, which indicates elongase enzyme activity 
was calculated as the oleate/palmitoleate (18:1c9/16:1) ratio. The ac-
tivity of stearoyl-CoA desaturase 1 (SCD1) was calculated using SCD1 
indices 1 and 2, which reflect the palmitoleate/palmitate (16:1/16:0) 
ratio and the oleate/stearate (18:1c9/18:0) ratio, respectively. The 
delta-(5)-desaturase (D5D) index was calculated with the arachidonate/ 
dihomo-γ-linolenate (20:4/20:3) ratio. The de novo lipogenesis index 
and the elongase index were higher (p  <  0.0001 and p = 0.0008 re-
spectively) and the SCD1 index 1 and 2 were lower (p  <  0.0001 for 
both) in the T1DM group compared to the controls. The D5D index was 
unchanged between the groups. 
3.3. Association between HbA1c concentration and plasma FFAs 
We examined the relationship between HbA1c concentration and 
plasma concentrations of the major FFA species (Fig. 4 and Table S4 
and S5). With the exception of α-linolenate (18:3) and dihomo-γ-lino-
lenate (20:3), all plasma FFA concentrations negatively correlated with 
HbA1c (p  <  0.0001 for myristate (14:0), palmitate (16:0), linoleate 
(18:2), oleate (18:1c9), cis-vaccenate (18:1c11) and stearate (18:0), 
p = 0.0145 for eicosapentaenoate (20:5), p = 0.0281 for arachidonate 
(20:4) and p = 0.0017 for docosahexanoate (22:6)). We then explored 
the relationships between HbA1c and the different FFA indices (Fig. 5). 
The plasma concentrations of total FFAs, saturated FFAs, unsaturated 
FFAs, n-6 FFAs and n-3 FFAs negatively correlated with HbA1c 
(p  <  0.0001, p  <  0.0001, p  <  0.0001, p = 0.0023 and p  <  0.0001 
respectively). The saturated/unsaturated FFA ratio did not show any 
correlation with HbA1c but the n-3/n-6 ratio positively associated with 
HbA1c (p = 0.0023). The SCD1 index negatively associated with 
HbA1c whether measured using either palmitoleate/palmitate (16:1/ 
16:0) or oleate/stearate ratios (18:1c9/18:0; p  <  0.0001 and 
p = 0.0003 respectively). The D5D index was not associated with 
HbA1c but the elongase and de novo lipogenesis indices each positively 
correlated with HbA1c (p = 0.0013 and  <  0.0001 respectively). We 
then assessed the relationship between HbA1c concentration and 
plasma concentrations of cholesterol, HDL, LDL and between HBA1c 
concentration and the cholesterol/HDL ratio and diabetes duration 
(Table S6). No associations between these respective parameters were 
found. 
3.4. Assessment of age and sex-dependent associations with lipid 
concentrations and of diabetes duration with plasma FFA concentrations 
The presence of sex or age-specific differences in the plasma con-
centrations of major FFA species was assessed. No differences in the 
plasma concentration of specific FFA species or in the indices monitored 
were found between males and females with T1DM (Fig. S1 and S2 and 
Table S7). There were no associations between age and the plasma 
concentration of major FFA species in T1DM, but the SCD1 index 1 
positively correlated with age (p = 0.0098), while the elongase index 
negatively correlated with age (p = 0.0363; Fig. S3 and S4 and Table 
S8). In controls, plasma concentrations of palmitate (16:0), linoleate 
(18:2), oleate (18:1c9), cis-vaccenate (18:1c11) and stearate (18:0) 
were negatively correlated with age (p = 0.0006, p = 0.0037, 
p = 0.0014, p = 0.0003 and p = 0.0007 respectively; Fig. S5). In 
addition, total plasma FFA concentration, total plasma concentration of 
saturated, unsaturated and n-6 FFAs (but not n-3) were negatively 
correlated with age (p = 0.0008, p = 0.0005, p = 0.0018 and 
Fig. 1. Plasma concentrations of HbA1c, lipids and HSA in T1DM and control individuals. Plasma concentrations of A. HbA1c, B. triglycerides, C. cholesterol, D. LDL, 
E. HDL, F. cholesterol/HDL ratio and G. HSA are presented for T1DM and controls. The concentrations of triglycerides, cholesterol, LDL and HDL and the cholesterol/ 
HDL ratio were not different in both groups. HbA1c concentration was higher in the T1DM group (p  <  0.0001) and HSA concentration was lower in the T1DM group 
(p = 0.0413). Statistically significant differences are indicated by * where p  <  0.05, ** where p  <  0.01 and *** where p  <  0.001. Where no significant differences 
were observed (p  >  0.05), it is denoted by ns. 
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p = 0.0031 respectively), while the D5D index was positively corre-
lated with age (p = 0.0057; Fig. S6). We examined the association 
between different lipids and the plasma concentrations of FFA species 
in T1DM (Table 2 and Fig. S7). LDL and the duration of diabetes were 
not correlated with any of the parameters. Cholesterol positively asso-
ciated with palmitoleate (16:1) and linoleate (18:2) concentrations and 
the SCD1 index 1 (p = 0.0210, p = 0.0041 and p = 0.0479, respec-
tively), and negatively associated with the de novo lipogenesis index 
(p = 0.0003). HDL positively associated with the plasma concentra-
tions of myristate (14:0), palmitate (16:0), linoleate (18:2), cis-vacce-
nate (18:1c11), stearate (18:0), total FFAs and total saturated FFAs 
(p = 0.0372, p = 0.0321, p = 0.0007, p = 0.0090, p = 0.0124, 
p = 0.0455 and p = 0.0212 respectively) and negatively associated 
with the de novo lipogenesis index (p = 0.0258). The cholesterol ratio 
positively associated with the SCD1 index 1 (p = 0.0424). 
4. Discussion 
The concentrations of specific plasma FFA species in individuals 
with T1DM has not been fully investigated before. Indeed, only one 
report of alterations in plasma FFA levels in T1DM has been made: a 
metabolomic study by Dutta et al. comparing individuals with T1DM 
with “good” or “bad” glycaemic controls (14 and 15 individuals, re-
spectively) and controls (14 matched with the individuals with T1DM 
and good glycaemic control and 15 matched with individuals with 
T1DM and bad glycaemic control) [19]. Using untargeted metabolomic 
analysis, this study found that individuals with T1DM with bad gly-
caemic control have reduced FFA levels. The authors then used targeted 
analysis on myristate (14:0), palmitoleate (16:1), palmitate (16:0), α- 
linolenate (18:3), linoleate (18:2), elaidate (18:1 trans), oleate (18:1 
cis), stearate (18:0) and arachidonate (20:4) and they found elevated 
levels of oleate, elaidate and stearate in individuals with T1DM and 
Fig. 2. Plasma concentrations of major FFA species in T1DM and control individuals measured by GC–MS. A. Typical GC–MS chromatogram showing FAME 
separation. B-M. Plasma concentrations of B. myristate (14:0), C. palmitoleate (16:1), D. palmitate (16:0), E. α-linolenate (18:3), F. linoleate (18:2), G. oleate 
(18:1c9), H. cis-vaccenate (18:1c11), I. stearate (18:0), J. eicosapentaenoate (20:5), K. arachidonate (20:4), L. dihomo-γ-linolenate (20:3) and M. docosahexaenoate 
(22:6) are presented for subjects with T1DM and controls. Plasma FFA concentrations were reduced in the T1DM group compared to the control group (p  <  0.0001 
for myristate, linoleate, oleate, cis-vaccenate, stearate and docosahexaenoate, p = 0.0020 for eicosapentaenoate, p = 0.0068 for arachidonate), except for α- 
linolenate and dihomo-γ-linolenate, which were not significantly changed. Statistically significant differences are indicated by * where p  <  0.05, ** where 
p  <  0.01 and *** where p  <  0.001. Where no significant differences were observed (p  >  0.05), it is denoted by ns. 
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good glycaemic control compared to healthy controls, while unchanged 
plasma FFA levels were found in individuals with T1DM and bad gly-
caemic control compared to healthy control. Here, FFAs were extracted 
from plasma taken from 45 individuals with T1DM and 45 controls and 
their concentrations were determined using GC–MS. Our cohort was 
age and sex-matched, but BMI was slightly higher in the T1DM group. 
HSA concentration was also lower in the T1DM group compared to the 
controls, which is in agreement with a study that found that insulin 
withdrawal in women with T1DM leads to reduced HSA synthesis [20]. 
Unchanged lipid (HDL, LDL, cholesterol and triglycerides) levels in 
individuals with T1DM have been reported before [21], and are thought 
to be the result of good glycaemic control [22]. The concentrations of 
total FFAs, and of most FFA species measured, were found to be reduced 
in the T1DM group compared to controls, in accord with the previous 
metabolomics study by Dutta et al. [19]. 
In order to fully understand our results, different fatty acid (FA) 
indices were calculated to indicate the activities of various enzyme 
classes involved in FA metabolism. The increase in n-3/n-6 ratio in the 
T1DM individuals was unexpected, as n-3 FAs in the sn2 position form a 
reservoir for the production of anti-inflammatory mediators [23]. In 
addition, a deficiency in n-3 FFAs may heighten inflammatory reactions 
and increase the risk of developing auto-immune diseases such as T1DM 
[24]. On the contrary, n-6 FAs form pro-inflammatory molecules, and 
so n-6 FFAs may have been expected to be elevated in T1DM. However, 
this view may be too simplistic as n-6 FFAs are also precursors of anti- 
inflammatory molecules and there is no epidemiological evidence 
suggesting that an increase intake of the n-6 FAs linoleate (18:2) and 
arachidonate (20:4) promotes inflammation. In addition, despite pre-
vious reports on the benefits of n-3 supplementation in children at risk 
of developing T1DM [24–27], a recent meta-analysis on the effect of n-3 
and n-6 FA supplementation in pregnancy or early life of children found 
no positive effect on T1DM occurrence [28]. 
Total saturated and unsaturated FFAs and the saturated/un-
saturated FFA ratio were then calculated. The fact that the saturated/ 
unsaturated ratio increased was expected, as this ratio and the nature of 
the unsaturated FAs in cellular membranes are important for the 
structure, fluidity and functioning of the cells. A study performed in 
children with one parent with T1DM has shown that those who then 
subsequently develop T1DM themselves had a higher proportion of 
polyunsaturated FAs in their phospholipids possibly due to altered lipid 
absorption [3]. The fact that the proportion of saturated FFAs is higher 
in plasma in our cohort could be due to differential absorption of FFAs 
by the cells (and incorporation into phospholipids) or to a difference in 
lipid profiles at different ages (our cohort being older). 
The de novo lipogenesis index is calculated as the ratio of palmitate 
(16:0, the main FFA synthesised by de novo lipogenesis) and linoleate 
(18:2, an essential FFA only obtained from the diet). The increase in this 
index in T1DM individuals compared to controls could be explained by 
an increase in lipogenesis, though it is unlikely as palmitate itself has a 
reduced concentration in T1DM. In addition, a study conducted on 9 
individuals with T1DM and 9 controls found unchanged levels of fasting 
or postprandial hepatic de novo lipogenesis [21]. Thus, the increase in 
lipogenesis index we measured was more probably due to either a re-
duced FFA intake from the diet or the reduced absorption of dietary 
Fig. 3. Plasma FFA indices in T1DM and control individuals. Plasma values are provided of A. Total plasma FFA concentration, B. total plasma concentration of 
saturated FFAs, C. total plasma concentration of unsaturated FFAs, D. saturated/unsaturated FFA ratio, E. total plasma concentration of n-3 FFAs, F. total plasma 
concentration of n-6 FFAs, G. n-3/n-6 FFA ratio, H. de novo lipogenesis index, I. SCD1 index 1, J. SCD1 index 2, K. elongase index, and L. D5D index are presented for 
T1DM and controls. Plasma concentration of total FFA, total saturated FFA, total unsaturated FFA, n-3 FFA and n-6 FFA and the SCD1 index 1 and SCD1 index 2 were 
reduced in the T1DM group (p  <  0.0001 for all). The saturated/unsaturated FFA and n-3/n-6 ratios and the de novo lipogenesis and elongase indices were increased 
in the T1DM group (p = 0.0166, p = 0.0089, p  <  0.0001 and p = 0.0008 respectively). The D5D index was unchanged. Statistically significant differences are 
indicated by * where p  <  0.05, ** where p  <  0.01 and *** where p  <  0.001. Where no significant differences were observed (p  >  0.05), it is denoted by ns. 
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FFAs. Changes in the dietary habits of individuals with T1DM after 
diagnosis is likely, as control of the diet is an important axis of T1DM 
management (NICE guidelines from the UK [NG17] and [NG18] 
[29,30]). Nevertheless, the results of studies investigating the dietary 
habits of individuals with T1DM compared to controls vary geo-
graphically. Indeed, while individuals in Spain have been noted to have 
on average better adherence to the Mediterranean Diet (low intake of 
animal fat, high intake of fruits, vegetables, grains, olive oil and mod-
erate intake of fish, poultry and red wine) compared to controls [31], a 
T1DM cohort from the USA consumed more fat and saturated fat 
compared to controls [32], while a T1DM cohort from China had a 
higher energy percentage from fat than controls [33]. Diet was not 
monitored in our UK cohort so it is not possible to evaluate the degree 
to which dietary differences may have influenced our results. However, 
altered absorption of dietary FFAs and altered lipid metabolism are 
likely to play a major role as FFAs have been noted to be the main 
energy source of the heart in T1DM individuals, replacing glucose [34]. 
In the T1DM group, SCD1 indices 1 and 2 decreased, meaning that a 
smaller proportion of palmitate (16:0) and stearate (18:0) were desa-
turated in T1DM individuals (explaining the higher proportion of sa-
turated FFAs), while the elongase index increased compared to controls, 
which meant that more palmitoleate (16:1) was converted into oleate 
(18:1c9). The D5D index was unchanged between the groups, implying 
that the rate of conversion dihomo-γ-linolenate (20:3) into arachido-
nate (20:4) was unchanged. Another study also showed reduced 
desaturation in T1DM, but contrary to our study also found elongation 
to be reduced [35]. This reduction of elongation may be explained by a 
difference in methodology leading to different enzymes being studied 
(reduced linoleate/arachidonate (18:2/20:4) ratio in serum cholesterol, 
serum phospholipids and erythrocytes or unchanged in serum trigly-
cerides and in platelets, versus our increased oleate/palmitoleate 
(18:1c9/16:1) ratio in plasma FFAs). 
The influence of sex, age, glucose control, diabetes duration, cho-
lesterol, LDL and HDL concentration on plasma FFA concentrations and 
lipid indices were examined. No sex difference in plasma FFA con-
centrations or lipid indices were observed in the T1DM group. This is in 
contrast to previously reported differences in lipid metabolism between 
men and women [36], but in accord with a previous study in healthy 
individuals that found no difference in most plasma FFA species con-
centrations between sexes and only a higher concentrations of doc-
osahexanoate (22:6) and total n-3 FFAs in women compared to men 
[37]. In healthy individuals, age was negatively correlated with the 
plasma concentrations of most FFAs and was positively correlated with 
the D5D index. In individuals with T1DM these associations were not 
present; the only effects with age were a positive correlation with SCD1 
index 1 but not SCD1 index 2, and a negative correlation with the 
elongase index. Day-long postprandial FFA concentrations have been 
reported to be lower in older non-diabetic individuals, which is in ac-
cord with our results in the control group [38]. The HbA1c con-
centration reflects the degree of control of plasma glucose 
Fig. 4. Associations between HbA1c concentration and plasma concentrations of major FFA species in subjects with T1DM and controls. A-L. Relationship between 
HbA1c and plasma concentrations of FFAs between subjects with T1DM and controls; A. myristate (14:0), B. palmitoleate (16:1), C. palmitate (C16:0), D. α-linolenate 
(18:3), E. linoleate (18:2), F. oleate (G18:1c9), G. cis-vaccenate (18:1c11), H. stearate (18:0), I. eicosapentaenoate (20:5), J. arachidonate (C20:4), K. dihomo-γ- 
linolenate (20:3) and L. docosahexaenoate (22:6). Blue circles represent samples from individuals from the T1DM group, red circles represent samples from in-
dividuals from the control group. With the exception of α-linolenate and dihomo-γ-linolenate, all plasma FFA concentrations negatively correlated with HbA1c 
(p  <  0.0001 for myristate, palmitate, linoleate, oleate, cis-vaccenate and stearate, p = 0.0145 for eicosapentaenoate, p = 0.0281 for arachidonate and p = 0.0017 
for docosahexanoate). Where correlations are significant, the p-value is provided. Where no significant correlation was observed (p  >  0.05), it is denoted by ns. 
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concentration, a direct or indirect controller of a wide range of meta-
bolic processes, including lipid metabolism [3,4]. The metabolomic 
study by Dutta et al. confirmed the importance of glycaemic control in 
lipid metabolism by revealing metabolic changes in individuals with 
T1DM who had poor glycaemic control, compared to those with good 
glycaemic control [19]. Thus, it is unsurprising to find that HbA1c 
concentration associates with the plasma concentration of most of the 
major FFA species. However, just as a diet high in fat is associated with 
poor glycaemic control [39], it would be expected that HbA1c levels 
would be positively associated with plasma FFA levels in T1DM. Here 
HbA1c was negatively correlated with the concentrations of the dif-
ferent plasma FFAs. In addition, the other changes observed in the 
T1DM group compared to the control group were also increased with 
poor glycaemic control, with the exception of the saturated/un-
saturated FFA ratio which was not associated with HbA1c level. Thus, 
either the expression or the function of the elongase and desaturase 
enzymes is likely to be regulated by plasma glucose levels. However, 
T1DM itself also affects their expression, with SCD1 having a reduced 
expression in the kidney in NOD mice with autoimmune diabetes [40]. 
It is unknown if some individuals with T1DM possess genetic mutations 
that result in altered desaturase or elongase expression or activity. 
Associations have previously been found between some specific FAs 
found in phospholipids and the concentrations of cholesterol, HDL or 
LDL: cholesterol concentration positively correlated with eicosa-
pentaenoate concentration (20:5) and HDL concentration with α-lino-
lenate (18:3) and eicosapentaenoate concentrations; LDL concentration 
positively correlated with eicosapentaenoate and docosahexaenoate 
(22:6) concentrations and negatively correlated with linoleate (18:2) 
concentrations, while no association was found with the concentrations 
of dihomo-γ-linolenate (20:3) and arachidonate (20:4) [41]. In our 
study, only minimal associations were found: the HDL concentration 
was positively correlated with the concentrations of total plasma FFAs, 
total saturated FFAs, and some FFAs (myristate (14:0), palmitate (16:0), 
linoleate (18:2), cis-vaccenate (18:1c11), stearate (18:0)), while the 
cholesterol concentration was positively correlated with the SCD1 
index 1 and with palmitoleate (16:1) and linoleate (18:2) FFA con-
centrations and negatively correlated with the de novo lipogenesis 
index. The cholesterol ratio was positively correlated with the SCD1 
index 1, while neither the diabetes duration nor the LDL concentration 
appeared to have any influence on plasma FFA concentrations. Thus, 
plasma HDL concentration and to a lesser degree, plasma cholesterol 
concentration seem to be closely associated with plasma FFA con-
centrations. While HDL concentration did not differ between our T1DM 
and control groups, HDL function is known to be reduced in T1DM 
Fig. 5. Associations between HbA1c concentration and different indices and FFA concentrations in T1DM and controls. Relationship between HbA1c concentration 
and A. total plasma FFA concentration, B. total plasma concentration of saturated FFAs, C. total plasma concentration of unsaturated FFAs, D. saturated/unsaturated 
FFA ratio, E. total plasma concentration of n-3 FFAs, F. total plasma concentration of n-6 FFAs, G. n-3/n-6 FFA ratio, H. de novo lipogenesis index, I. SCD1 index 1, J. 
SCD1 index 2, K. elongase index, and L. D5D index are presented for T1DM and controls. Blue circles represent samples from individuals from the T1DM group, red 
circles represent samples from individuals from the control group. In T1DM and controls, HbA1c concentration was negatively correlated with plasma concentrations 
of total FFAs, total saturated FFAs, total unsaturated FFAs, total n-3 FFAs and total n-6 FFAs and with SCD1 index1 and SCD1 index 2 (p  <  0.0001, p  <  0.0001, 
p  <  0.0001, p = 0.0023, p  <  0.0001, p  <  0.0001 and p = 0.0003 respectively) and positively correlated with the n-3/n-6 FFA ratio, the de novo lipogenesis index 
and the elongase index (p = 0.0023, p  <  0.0001 and p = 0.0013 respectively). Where correlations are significant, the p-value is provided. Where no significant 
correlation was observed (p  >  0.05), it is denoted by ns. 
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[42]. 
In conclusion, this study greatly enhances previous knowledge of 
how plasma FFA metabolism is altered in T1DM. These alterations in-
clude reductions in the plasma concentrations of most major FFA spe-
cies, increases in saturated/unsaturated FFA ratios, n-3/n-6 FFA ratio, 
de novo lipogenesis index and elongase index and decreases in SCD1 
indices 1 and 2, with those differences most prevalent in those with 
poor glycaemic control. Current studies prevent us from asserting the 
extent to which diet is responsible for the altered lipid profile we ob-
serve or if there is an altered absorption of dietary FFAs in T1DM. De 
novo lipogenesis itself is unlikely to be increased, but lipogenesis pro-
ducts are more predominant within the lipid profile in T1DM, possibly 
due to altered diet or alerted dietary absorption of FFAs. Thus, while 
part of these results could potentially reflect the dietary changes, they 
also reflect strong alterations in lipid metabolism, particularly in FA 
desaturation and elongation. The alterations in lipid metabolism may 
have important consequences for metabolic regulation, in particular for 
inflammation, cellular function and oxidative stress management, 
through alteration of cellular membrane composition, activation of FA 
receptors and precursor availability for the synthesis of signalling mo-
lecules. The results highlighted by our study are important, as differ-
ences in lipid metabolism may be a key driver of complications in in-
dividuals with the disease. Therefore, these data may be useful not only 
in increasing our understanding of T1DM but also for management of 
the disease. 
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